254 related articles for article (PubMed ID: 15219169)
1. New oncology strategy: molecular targeting of cancer cells.
Capriotti T
Medsurg Nurs; 2004 Jun; 13(3):191-5. PubMed ID: 15219169
[No Abstract] [Full Text] [Related]
2. Cancer research. Taking garbage in, tossing cancer out?
Garber K
Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
[No Abstract] [Full Text] [Related]
3. Molecule of the month. Bortezomib.
Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
[No Abstract] [Full Text] [Related]
4. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
5. [Breast cancer and Her-2].
Hatake K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144
[No Abstract] [Full Text] [Related]
6. First proteasome inhibitor approved for multiple myeloma.
Twombly R
J Natl Cancer Inst; 2003 Jun; 95(12):845. PubMed ID: 12813164
[No Abstract] [Full Text] [Related]
7. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
8. Targeted therapies in breast cancer: challenging questions from oncology nurses.
Becze E
ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
[No Abstract] [Full Text] [Related]
9. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
Satou Y; Matsuoka M
Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
[TBL] [Abstract][Full Text] [Related]
10. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Kelley TW; Alkan S; Srkalovic G; Hsi ED
Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib as a potential treatment for prostate cancer.
Papandreou CN; Logothetis CJ
Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Politou M; Naresh K; Terpos E; Crawley D; Lampert I; Apperley JF; Rahemtulla A
Acta Haematol; 2005; 114(3):170-3. PubMed ID: 16227683
[No Abstract] [Full Text] [Related]
14. The proteasome: a new target for novel drug therapies.
Elliott PJ; Ross JS
Am J Clin Pathol; 2001 Nov; 116(5):637-46. PubMed ID: 11710679
[TBL] [Abstract][Full Text] [Related]
15. Targeting proteasome inhibition in hematologic malignancies.
Hideshima T; Richardson PG; Anderson KC
Rev Clin Exp Hematol; 2003 Jun; 7(2):191-204. PubMed ID: 14763162
[TBL] [Abstract][Full Text] [Related]
16. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
18. Keys to unlock cancer: targeted therapy.
Viele CS
Oncol Nurs Forum; 2005 Sep; 32(5):935-40. PubMed ID: 16136192
[No Abstract] [Full Text] [Related]
19. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of the proteasome in leukaemia.
McCloskey SM; McMullin MF; Walker B; Irvine AE
Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
